BR112019002168A2 - anticorpos trivalentes bispecíficos ligantes a claudina6 ou claudina18.2 e cd3 para o tratamento de doenças cancerígenas que expressam claudina - Google Patents
anticorpos trivalentes bispecíficos ligantes a claudina6 ou claudina18.2 e cd3 para o tratamento de doenças cancerígenas que expressam claudinaInfo
- Publication number
- BR112019002168A2 BR112019002168A2 BR112019002168A BR112019002168A BR112019002168A2 BR 112019002168 A2 BR112019002168 A2 BR 112019002168A2 BR 112019002168 A BR112019002168 A BR 112019002168A BR 112019002168 A BR112019002168 A BR 112019002168A BR 112019002168 A2 BR112019002168 A2 BR 112019002168A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- treatment
- binding
- claudin6
- bispecific trivalent
- Prior art date
Links
- 102000002029 Claudin Human genes 0.000 title abstract 2
- 108050009302 Claudin Proteins 0.000 title abstract 2
- 201000009030 Carcinoma Diseases 0.000 title 1
- 102000003859 Claudin-6 Human genes 0.000 title 1
- 108090000229 Claudin-6 Proteins 0.000 title 1
- 239000011230 binding agent Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2016/072688 WO2018054484A1 (en) | 2016-09-23 | 2016-09-23 | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| PCT/EP2017/073773 WO2018054973A1 (en) | 2016-09-23 | 2017-09-20 | Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019002168A2 true BR112019002168A2 (pt) | 2019-09-17 |
Family
ID=57003498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019002168A BR112019002168A2 (pt) | 2016-09-23 | 2017-09-20 | anticorpos trivalentes bispecíficos ligantes a claudina6 ou claudina18.2 e cd3 para o tratamento de doenças cancerígenas que expressam claudina |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11787862B2 (enExample) |
| EP (2) | EP3515939A1 (enExample) |
| JP (2) | JP7055794B2 (enExample) |
| KR (2) | KR20230074637A (enExample) |
| CN (2) | CN118388656A (enExample) |
| AU (3) | AU2017331331B2 (enExample) |
| BR (1) | BR112019002168A2 (enExample) |
| CA (1) | CA3034186A1 (enExample) |
| IL (3) | IL264233B (enExample) |
| MX (2) | MX2019003350A (enExample) |
| NZ (1) | NZ750132A (enExample) |
| SG (1) | SG11201901899PA (enExample) |
| WO (2) | WO2018054484A1 (enExample) |
| ZA (2) | ZA201900962B (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2647707T (lt) | 2010-11-30 | 2018-11-12 | Chugai Seiyaku Kabushiki Kaisha | Citotoksiškumą indukuojantis terapinis agentas |
| IL301638B2 (en) | 2017-09-29 | 2024-09-01 | Daiichi Sankyo Co Ltd | Antibody-pyrrolobenzodiazepine derivative conjugate |
| US11912763B2 (en) | 2018-06-17 | 2024-02-27 | L & L Biopharma Co., Ltd. | Antibody targeting CLDN18.2, bispecific antibody, ADC, and CAR, and applications thereof |
| WO2020018852A2 (en) * | 2018-07-18 | 2020-01-23 | Askgene Pharma Inc. | Novel antibodies and methods for making and using the same |
| CN112512581B (zh) * | 2018-08-03 | 2024-12-17 | 安进研发（慕尼黑）股份有限公司 | 针对cldn18.2和cd3的抗体构建体 |
| EP3891183A4 (en) * | 2018-12-07 | 2022-08-31 | Zlip Holding Limited | ANTI-CLAUDIN ANTIBODIES AND USES THEREOF |
| CN113166246B (zh) * | 2018-12-28 | 2024-10-18 | 四川科伦博泰生物医药股份有限公司 | 一种抗体及其用途 |
| CN109762067B (zh) * | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
| JP2022523749A (ja) * | 2019-02-01 | 2022-04-26 | クレージュ メディカル カンパニー，リミテッド | Ｔｃｒ融合タンパク質およびｔｃｒ融合タンパク質を発現する細胞 |
| KR20210128443A (ko) | 2019-02-15 | 2021-10-26 | 인테그럴 몰큘러 인코포레이티드 | 클라우딘 6 항체 및 이의 용도 |
| JP2022527173A (ja) * | 2019-03-29 | 2022-05-31 | フェインズ セラピューティクス，インコーポレーテッド | ヒト化抗クローディン１８．２キメラ抗原受容体及びその使用 |
| US12428478B2 (en) * | 2019-04-01 | 2025-09-30 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-Claudin 18.2 antibody and application thereof |
| KR102239781B1 (ko) * | 2019-04-08 | 2021-04-13 | 주식회사 녹십자 | Gpnmb 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도 |
| CN111944048B (zh) * | 2019-05-16 | 2023-10-03 | 启愈生物技术(上海)有限公司 | 抗cldn抗体及其药物组合物和检测方法 |
| CN113950485A (zh) * | 2019-07-10 | 2022-01-18 | 中外制药株式会社 | 密蛋白-6结合分子及其用途 |
| KR20250044762A (ko) * | 2019-07-17 | 2025-04-01 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | Claudin18 항체 및 암 치료 방법 |
| AU2020329466B2 (en) * | 2019-08-12 | 2024-08-01 | Abl Bio Inc. | Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof |
| SG11202104264TA (en) * | 2020-03-31 | 2021-11-29 | Chugai Pharmaceutical Co Ltd | Claudin-6 targeting multispecific antigen-binding molecules and uses thereof |
| WO2021237717A1 (zh) * | 2020-05-29 | 2021-12-02 | 武汉友芝友生物制药有限公司 | 抗cldn18.2和cd3的双特异性抗体 |
| JP7620780B2 (ja) * | 2020-06-30 | 2025-01-24 | ノナ・バイオサイエンシーズ・（シャンハイ）・カンパニー・リミテッド | Ｈ２Ｌ２とＨＣＡｂ構造を有する結合タンパク質 |
| CN114106195B (zh) * | 2020-08-27 | 2024-09-17 | 盛禾(中国)生物制药有限公司 | 一种多功能融合蛋白及其用途 |
| CR20230235A (es) * | 2020-11-06 | 2023-10-05 | Amgen Res Munich Gmbh | Construcciones polipeptídicas que se unen selectivamente a cldn6 y cd3 |
| EP4245317A4 (en) * | 2020-11-10 | 2024-11-06 | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. | BISPECIFIC ANTIBODY FOR CLAUDIN 18A2 AND CD3 AND APPLICATION OF BISPECIFIC ANTIBODY |
| JP2024511319A (ja) | 2021-03-09 | 2024-03-13 | ゼンコア インコーポレイテッド | Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体 |
| CN114853897B (zh) * | 2021-04-15 | 2024-01-26 | 北京大学深圳研究生院 | 抗cd19/cd22/cd3三特异性抗体及用途 |
| EP4349870A1 (en) * | 2021-06-02 | 2024-04-10 | Qure Biotechnology (Shanghai) Co., Ltd. | Anti-cd3 antibody variant, fusion protein, and application |
| EP4355784A1 (en) * | 2021-06-15 | 2024-04-24 | Xencor, Inc. | Heterodimeric antibodies that bind claudin18.2 and cd3 |
| WO2022262959A1 (en) * | 2021-06-15 | 2022-12-22 | Astellas Pharma Europe Bv | Bispecific binding agents binding to cldn18.2 and cd3 |
| EP4370551A1 (en) * | 2021-07-15 | 2024-05-22 | BioNTech SE | Agents encoding cldn6 and cd3 binding elements for treating cldn6-positive cancers |
| WO2023010068A2 (en) * | 2021-07-28 | 2023-02-02 | Cartesian Therapeutics, Inc. | Multiprotein-engineered cells secreting a multispecific antibody |
| JP2025510323A (ja) * | 2022-03-28 | 2025-04-14 | フォートビタ バイオロジクス（シンガポール）プライベート リミティド | 抗Ｃｌａｕｄｉｎ１８．２とＣＤ３二重特異性抗体を含む製剤およびその調製方法と使用 |
| US20240368299A1 (en) * | 2022-04-28 | 2024-11-07 | Xintrum Pharmaceuticals, Ltd. | Anti-human CD73 monoclonal antibody without hook effect |
| IL319951A (en) | 2022-11-30 | 2025-05-01 | Integral Molecular Inc | Antibodies targeting claudin 6, including its bispecific formats |
| AU2023393653A1 (en) * | 2022-12-14 | 2025-05-22 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
| WO2024184810A1 (en) * | 2023-03-06 | 2024-09-12 | Beigene Switzerland Gmbh | Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use |
| WO2024197709A1 (zh) * | 2023-03-30 | 2024-10-03 | 中国科学院深圳先进技术研究院 | 一种t细胞衔接器及其制备方法和应用 |
| CN116087069B (zh) * | 2023-04-10 | 2023-08-08 | 苏州药明康德新药开发有限公司 | 一种基于流式细胞术检测特定细胞群体组蛋白甲基化和乙酰化修饰水平的方法 |
| WO2024243093A2 (en) * | 2023-05-19 | 2024-11-28 | The Regents Of The University Of California | Multispecific antibodies targeting cd3 and cd22 |
| WO2024243561A1 (en) | 2023-05-25 | 2024-11-28 | The Regents Of The University Of California | Methods of treating cancer |
| KR20240176948A (ko) * | 2023-06-15 | 2024-12-26 | 에이비온 주식회사 | 소세포폐암 진단 및 치료를 위한 타겟으로서 클라우딘-3의 용도 |
| WO2025120866A1 (en) * | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025121445A1 (en) * | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025162454A1 (zh) * | 2024-02-02 | 2025-08-07 | 北京昌平实验室 | 双特异性抗体和细胞因子融合蛋白及其应用 |
| WO2025231015A1 (en) * | 2024-04-30 | 2025-11-06 | Context Therapeutics Inc. | Compositions comprising bispecific antibodies that bind to claudin 6 and cd3, and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2004035607A2 (en) | 2002-10-17 | 2004-04-29 | Genmab A/S | Human monoclonal antibodies against cd20 |
| CN1326881C (zh) | 2003-09-29 | 2007-07-18 | 中国人民解放军军事医学科学院基础医学研究所 | 一种三价双特异性抗体，其制备方法及用途 |
| US20090004213A1 (en) | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| WO2014075697A1 (en) * | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
| UA128182C2 (uk) * | 2012-11-13 | 2024-05-01 | Біонтех Аґ | Агенти для лікування експресуючих клаудин ракових захворювань |
| US9605084B2 (en) * | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| ES2699753T3 (es) * | 2014-01-29 | 2019-02-12 | Biontech Ag | Mimótopos peptídicos de claudina 18.2 y sus usos |
| EP2982693A1 (en) * | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | CD3 binding domain |
| PL3227332T3 (pl) * | 2014-12-03 | 2020-06-15 | F. Hoffmann-La Roche Ag | Wielospecyficzne przeciwciała |
| KR102495820B1 (ko) | 2014-12-19 | 2023-02-06 | 치오메 바이오사이언스 가부시키가이샤 | 5t4 및 cd3에 대한 3개 결합 도메인을 포함하는 융합 단백질 |
| WO2016135239A1 (en) * | 2015-02-25 | 2016-09-01 | Biotecnol Limited | Fusion protein comprising three binding domains to her2 |
| WO2022262959A1 (en) * | 2021-06-15 | 2022-12-22 | Astellas Pharma Europe Bv | Bispecific binding agents binding to cldn18.2 and cd3 |
-
2016
- 2016-09-23 WO PCT/EP2016/072688 patent/WO2018054484A1/en not_active Ceased
-
2017
- 2017-09-20 US US16/335,373 patent/US11787862B2/en active Active
- 2017-09-20 SG SG11201901899PA patent/SG11201901899PA/en unknown
- 2017-09-20 EP EP17776979.1A patent/EP3515939A1/en not_active Withdrawn
- 2017-09-20 WO PCT/EP2017/073773 patent/WO2018054973A1/en not_active Ceased
- 2017-09-20 EP EP22160052.1A patent/EP4043494A1/en active Pending
- 2017-09-20 MX MX2019003350A patent/MX2019003350A/es unknown
- 2017-09-20 CN CN202410521871.1A patent/CN118388656A/zh active Pending
- 2017-09-20 CA CA3034186A patent/CA3034186A1/en active Pending
- 2017-09-20 KR KR1020237017307A patent/KR20230074637A/ko not_active Ceased
- 2017-09-20 JP JP2019515626A patent/JP7055794B2/ja active Active
- 2017-09-20 KR KR1020197008288A patent/KR102537091B1/ko active Active
- 2017-09-20 BR BR112019002168A patent/BR112019002168A2/pt unknown
- 2017-09-20 CN CN201780056781.8A patent/CN110023336B/zh active Active
- 2017-09-20 AU AU2017331331A patent/AU2017331331B2/en active Active
- 2017-09-20 NZ NZ750132A patent/NZ750132A/en unknown
-
2019
- 2019-01-14 IL IL264233A patent/IL264233B/en unknown
- 2019-02-14 ZA ZA2019/00962A patent/ZA201900962B/en unknown
- 2019-03-22 MX MX2023005375A patent/MX2023005375A/es unknown
-
2020
- 2020-05-06 ZA ZA2020/02471A patent/ZA202002471B/en unknown
-
2022
- 2022-01-17 AU AU2022200283A patent/AU2022200283A1/en not_active Abandoned
- 2022-01-30 IL IL290234A patent/IL290234A/en unknown
- 2022-01-30 IL IL290230A patent/IL290230A/en unknown
- 2022-04-06 JP JP2022063389A patent/JP7436552B2/ja active Active
-
2023
- 2023-09-15 US US18/468,103 patent/US20240158501A1/en active Pending
-
2025
- 2025-04-16 AU AU2025202697A patent/AU2025202697A1/en not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019002168A2 (pt) | anticorpos trivalentes bispecíficos ligantes a claudina6 ou claudina18.2 e cd3 para o tratamento de doenças cancerígenas que expressam claudina | |
| EA201890390A8 (ru) | БИСПЕЦИФИЧЕСКИЕ КОНСТРУКТЫ АНТИТЕЛ, СВЯЗЫВАЮЩИЕ EGFRvIII И CD3 | |
| UY37928A (es) | Anticuerpos anti-cd38 y métodos de uso | |
| CR20200171A (es) | Contorsbodies 2 + 1 biespecíficos | |
| MX2021011696A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123. | |
| CO2020013089A2 (es) | Anticuerpos contra mica y/o micb y sus usos | |
| BR112018001374A2 (pt) | construtos de anticorpo biespecíficos que se ligam a egfrviii e cd3 | |
| MX2021005008A (es) | Moduladores de celulas t reguladoras multivalentes. | |
| EA201792193A1 (ru) | Конструкции биспецифического антитела для cdh3 и cd3 | |
| PH12018500241A1 (en) | Antibody constructs for dll3 and cd3 | |
| PH12018500295B1 (en) | Chimeric antigen receptors based on single-domain antibodies and methods of use thereof | |
| EA201890382A1 (ru) | Конструкции антител для cd70 и cd3 | |
| PH12020552006A1 (en) | Antibodies specific for cd3 and uses thereof | |
| NZ759835A (en) | Cd38 modulating antibody | |
| BR112018075901A2 (pt) | anticorpo humanizado ou fragmento de ligação a anticorpo, uso deste, complexo in vitro, opcionalmente isolado, e método in vitro | |
| UY38432A (es) | Anticuerpo monoclonal que se une específicamente al antígeno cd20 | |
| MY195946A (en) | Antibody Constructs for DLL3 and CD3 | |
| EA201890336A1 (ru) | Конструкции биспецифических антител, связывающиеся с дпб3 (dll3) и кд3 (cd3) | |
| BR112017002729A2 (pt) | terapia de combinação para uso em um método para tratar um tumor sólido em um indivíduo, anticorpo, uso, composição farmacêutica, kit para tratar um tumor sólido, e, método para tratar um tumor sólido em um indivíduo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122022025795-0 PROTOCOLO 870220118574 EM 16/12/2022 14:16. |